Kevin Kalinsky
Emory University Hospital/Winship Cancer Institute · SWOG Cancer Research Network · Emory University Winship Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kevin Kalinsky as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:23 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07862751 · US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and ChemotherapyEmory University · not yet recruiting · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma · principal investigator
- Ph3NCT07802626 · Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingSWOG Cancer Research Network · not yet recruiting · HR Positive/HER-2 Negative Breast Cancer · principal investigator
- Ph1/Ph2NCT06460298 · ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast CancerProDa BioTech, LLC · recruiting · Triple Negative Breast Cancer · principal investigator
- Ph1NCT02632071 · ACY-1215 + Nab-paclitaxel in Metastatic Breast CancerColumbia University · completed · Metastatic Breast Cancer, Breast Carcinoma · principal investigator
- Ph1NCT01650506 · Study of Erlotinib and Metformin in Triple Negative Breast CancerColumbia University · completed · Breast Cancer · principal investigator
- Ph2NCT01319539 · MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast CancerNational Cancer Institute (NCI) · terminated · Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative · principal investigator
- Ph1NCT01010958 · Adjuvant Valproate for High Grade SarcomasColumbia University · terminated · High Grade Sarcoma · principal investigator
- Ph2NCT00700882 · Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By SurgeryEastern Cooperative Oncology Group · completed · Melanoma (Skin) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Identifying leptomeningeal metastasis from breast cancer utilizing a novel immunocytochemical microfluidic deviceR03CA208547 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2016 to 2017 · $80,000 awarded in 2017Same name and institution; not confirmed by an ID
- Pre-Surgical trial of Metformin and Atorvastatin in Operable Breast CancerR03CA186931 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2014 to 2015 · $80,000 awarded in 2015Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · fiscal years 2015 to 2026Named on NCT07862751
- Systems Biology of Tumor Progression and Drug ResistanceU01CA168426 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · fiscal years 2016Named on NCT02632071
- Chemical Synthesis Shared ResourceP30CA013330 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Juan Pablo Maianti · fiscal years 2015 to 2026Named on NCT01319539
- ECOG-ACRIN Network Group Statistics and Data Management CenterU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · fiscal years 2015 to 2026Named on NCT00700882
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 09:23 UTC. The ranking covers the 200 most relevant of 58 PubMed records, and a shared surname and initials can bring in a namesake. All 58 on PubMed
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.N Engl J Med · 20211,463 citationsRCR 83.1
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.N Engl J Med · 2021778 citationsRCR 43.5
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.N Engl J Med · 2019713 citationsRCR 26.7
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.J Clin Oncol · 2017349 citationsRCR 10.7
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.Cancer Cell · 2021307 citationsRCR 13.7
- 296 citationsRCR 14.0
- Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.N Engl J Med · 2024263 citationsRCR 33.0
- 201 citationsRCR 16.1
- 193 citationsRCR 45.2
- First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.N Engl J Med · 2025177 citationsRCR 36.0